<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676572</url>
  </required_header>
  <id_info>
    <org_study_id>08/H0708/29</org_study_id>
    <secondary_id>CRO1014</secondary_id>
    <nct_id>NCT00676572</nct_id>
  </id_info>
  <brief_title>p38 Mitogen−Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma</brief_title>
  <official_title>p38 MAPK Activation as the Basis for Corticosteroid Insensitivity in Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aims to find out how the inflammation in patients suffering from severe asthma
      is different from that in non−severe asthma, and how it may prevent corticosteroids from
      working efficiently in severe asthma.

      It will look,in particular, at a protein enzyme called p38 mitogen−activated protein kinase
      (p38 MAPK for short)which controls the activation of several important pathways in the cell.
      We wish to find out whether this enzyme is more active in cells obtained from patients with
      severe asthma compared to those with non−severe asthma. We would like to understand how this
      enzyme can cause the cell to respond less well to the anti−inflammatory effects of
      corticosteroids. We also wish to find out whether any specific inhibitors of p38 MAPK can
      improve severe asthma by improving the effects of corticosteroids on these cells.

      We hypothesise that activation of the intracellular MAPK signalling pathway underlies the
      inflammatory processes of severe asthma, and leads to the diminution of the anti-inflammatory
      actions of CS through histone modification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN Comparative study to analyse differences in the characteristics of lung macrophages
      and blood monocytes between non-severe and severe asthmatics.

      AIMS

        1. To determine whether there are differences in terms of cell expression and activation
           between lung macrophages and blood monocytes from non-severe and severe asthma

        2. To determine the mechanisms of the lung macrophage and blood monocyte relative
           resistance to the effect of corticosteroids in severe asthma, and particularly focus on
           the role of p38 MAPK

        3. To determine the differences in airway smooth muscle cells between non-severe and severe
           asthma

      OUTCOME MEASURES

        1. Clinically the differences in inflammatory and remodelling markers between non-severe
           and severe asthma

        2. Differences in histone phosphorylation, NF-kB activity and glucocorticoid receptor
           activation and actions in macrophages and monocytes between non- severe and severe
           asthma

        3. Differences in behaviour of airway smooth muscle cells cultured from biopsies obtained
           from non-severe and severe asthma

      Severe and non-severe asthmatic subjects will be classified following ATS criteria. They
      undergo spirometry with reversibility testing, PC20, skin prick tests, exhaled nitric oxide
      measurements and induced sputum. They will have blood taken for PBMCs and undergo fiberoptic
      bronchoscopy for obtention of alveolar macrophages and bronchial biopsies
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Activity and Downstream Activity of the p38 MAPK Activity in Macrophages or PBMCs Between Those From Severe and Non−Severe Asthmatics</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in the Effect of p38 MAPK Inhibitor in Dexamethasone−Inhibition of Cytokine Release From Alveolar Macrophages and PBMCs Between Severe and Non−Severe Asthmatics</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of Suppression of IL6 release by p38 MAPK inhibitor</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Severe asthma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-severe asthma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fiberoptic bronchoscopy; blood test</intervention_name>
    <description>Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
    <arm_group_label>Non-severe asthma</arm_group_label>
    <arm_group_label>Severe asthma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      sputum cell pellets and supernatant; BAL supernatant; endobronchial biopsies; smooth muscle
      cell culture from biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Asthmatic subjects will be recruited from asthma clinics at the Royal Brompton Hospital and
        from primary care clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60

          -  Physician diagnosis of asthma

        Non-severe asthmatic subjects:

          -  mild to moderately severe asthma.

          -  The groups will be defined as follows, according to their need for treatments (as
             established in the Asthma Management GINA or BTS guidelines):

               1. Mild: intermittent symptoms and need for reliever bronchodilator less than once a
                  day

               2. moderate asthma: well-controlled asthma with minimal symptoms while on inhaled
                  corticosteroid therapy not exceeding 2,000 μg beclomethasone equivalent.

        Severe asthmatic subjects:

          -  will have at least 1 major and 2 minor criteria (as below) Major characteristics (at
             least one of the following criteria)

               -  Treatment with continuous or near continuous (&gt;50% of year) oral corticosteroids

               -  Requirement for treatment with high dose inhaled corticosteroids (ICS) Minor
                  characteristics (at least 2 out of the following)

                    1. Requirement for daily treatment with a controller medication in addition to
                       ICS e.g. LABA, theophylline, leukotriene antagonist

                    2. Asthma symptoms requiring SABA on a daily or near daily basis

                    3. Persistent airways obstruction (FEV1 &lt;80% predicted, diurnal PEF variation
                       &gt;20%)

                    4. One or more emergency care visits for asthma per year

                    5. 3 or more steroid &quot;bursts&quot; per year

                    6. Prompt deterioration with ≤ 25% reduction in oral or ICS

                    7. Near fatal asthma event in the past

        Exclusion Criteria:

          -  Current smokers, or less than 3 years since quitting smoking (&lt; 5 pack/years)

          -  Less than 4 weeks from an exacerbation

          -  On steroid-sparing agent or immunosuppressant such as azathioprine, methotrexate and
             ciclosporin

          -  Concomitant anti-IgE therapy

          -  On anti-platelet or anti-coagulant drugs

          -  Low platelet count

          -  Pregnancy or breast-feeding

          -  Intubation for asthma within 6 months of entry into this study (if undergoing
             bronchoscopy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kian F Chung, MBBS MD FRCP DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pankaj Bhavsar, BSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma Laboratory, Royal Brompton Hospital, Sydney Street</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J. 2010 Apr;35(4):750-6. doi: 10.1183/09031936.00071309. Epub 2009 Oct 19.</citation>
    <PMID>19840967</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <results_first_submitted>September 12, 2019</results_first_submitted>
  <results_first_submitted_qc>September 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2019</results_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imperial College London</investigator_affiliation>
    <investigator_full_name>Fan Chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>severe asthma</keyword>
  <keyword>corticosteroid insensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Severe Asthma</title>
          <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
        </group>
        <group group_id="P2">
          <title>Non-severe Asthma</title>
          <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Severe Asthma</title>
          <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
        </group>
        <group group_id="B2">
          <title>Non-severe Asthma</title>
          <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="2.67"/>
                    <measurement group_id="B2" value="32.8" spread="3.88"/>
                    <measurement group_id="B3" value="39.9" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Activity and Downstream Activity of the p38 MAPK Activity in Macrophages or PBMCs Between Those From Severe and Non−Severe Asthmatics</title>
        <time_frame>3 years</time_frame>
        <population>Data no collected</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
          </group>
          <group group_id="O2">
            <title>Non-severe Asthma</title>
            <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Activity and Downstream Activity of the p38 MAPK Activity in Macrophages or PBMCs Between Those From Severe and Non−Severe Asthmatics</title>
          <population>Data no collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in the Effect of p38 MAPK Inhibitor in Dexamethasone−Inhibition of Cytokine Release From Alveolar Macrophages and PBMCs Between Severe and Non−Severe Asthmatics</title>
        <description>Percentage of Suppression of IL6 release by p38 MAPK inhibitor</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
          </group>
          <group group_id="O2">
            <title>Non-severe Asthma</title>
            <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in the Effect of p38 MAPK Inhibitor in Dexamethasone−Inhibition of Cytokine Release From Alveolar Macrophages and PBMCs Between Severe and Non−Severe Asthmatics</title>
          <description>Percentage of Suppression of IL6 release by p38 MAPK inhibitor</description>
          <units>percentage of suppression of IL6 release</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="20"/>
                    <measurement group_id="O2" value="8" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>calculated p values</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Severe Asthma</title>
          <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
        </group>
        <group group_id="E2">
          <title>Non-severe Asthma</title>
          <description>Fiberoptic bronchoscopy; blood test: Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Kian Fan Chung</name_or_title>
      <organization>Imperial College London</organization>
      <phone>00442075947954</phone>
      <email>f.chung@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

